Newsroom

OAKVILLE, Ontario--(BUSINESS WIRE)--Algonquin Power & Utilities Corp. (TSX/NYSE: AQN) (“AQN”, “Algonquin” or the “Company”) today announced the appointment of Peter Norgeot as Chief Operating Officer (COO), effective immediately. Mr. Norgeot joins Algonquin after having recently retired as COO from Entergy Corporation (NYSE: ETR) (“Entergy”) and will be responsible for leading the Company’s electric, gas, and water regulated utility operations, capital execution, and enterprise-wide operati...

WOODSTOCK, Ill.--(BUSINESS WIRE)--Other World Computing (OWC®), a trusted leader in high-performance storage, memory, connectivity, software, and accessories that empower creative and business professionals to maximize performance, enhance reliability, and streamline workflows, today announced a major capacity expansion for its OWC ThunderBlade X12 production shuttle RAID SSD – doubling max capacity to 192TBs. This makes the OWC ThunderBlade X12 the first and only Thunderbolt 5 RAID shuttle dri...

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Eurozone AlphaDEX UCITS ETF 02.01.2026 FEUZ IE00B8X9NY41 1,105,638.00 EUR  64,092,879.84   57.969  ...

HARRISBURG, Pa.--(BUSINESS WIRE)--Mid Penn Bancorp, Inc. (NASDAQ: MPB) (“Mid Penn”), parent company of Mid Penn Bank, announced today that its acquisition of Sarasota, FL-based Cumberland Advisors, Inc. (“Cumberland”) was completed on January 1, 2026. A registered investment advisory firm with clients both nationally and internationally, Cumberland had approximately $3.2 billion in assets under management as of December 31, 2025. In connection with the acquisition, Cumberland has been merged wi...

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Emerging Markets AlphaDEX UCITS ETF 02.01.2026 FEM IE00B8X9NX34  325,002.00 USD  13,908,902.87   42.796  ...

CHARLOTTE, N.C.--(BUSINESS WIRE)--Krispy Kreme, Inc. (NASDAQ: DNUT) (“Krispy Kreme” or the “Company”), today announced that the Company will host a fireside chat at the 28th Annual ICR Conference on Monday, January 12, 2026 at 9:00 AM Eastern Time. A live webcast of the fireside chat will be accessible through the Events & Presentations section of Krispy Kreme’s website at investors.krispykreme.com. A replay of the webcast along with related materials will be available on the website for 90...

DENVER--(BUSINESS WIRE)--Lumen Technologies, Inc. (“Lumen,” “us,” “we” or “our”) (NYSE: LUMN) today announced that its wholly-owned subsidiary, Level 3 Financing, Inc. (“Level 3 Financing”), plans to offer an additional $600 million aggregate principal amount of its 8.500% Senior Notes due 2036 (the “Additional Notes”). The Additional Notes are being offered as a further issuance of Level 3 Financing's 8.500% Senior Notes due 2036, of which $1.25 billion aggregate principal amount was originall...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, Calif. on Monday, Jan. 12, 2026 at 12:00 p.m. E.T. / 9:00 a.m. P.T. Following the presentation there will be a Q&A session starting at 12:20 p.m. E.T. / 9:20 a.m. P.T. The presentation will be webcast live under the Events & Presen...

WEST PALM BEACH, Fla. & ZEPHYR COVE, Nev.--(BUSINESS WIRE)--Hennessy Capital Investment Corp. VII (NASDAQ: HVII) (“Hennessy VII”), and ONE Nuclear Energy LLC (“ONE Nuclear”), an independent developer of large-scale energy solutions powered by natural gas and advanced nuclear technologies, today announced that Hennessy VII filed a registration statement on Form S-4 with the U.S. Securities and Exchange Commission (“SEC”) on December 23, 2025, in connection with their previously announced propose...

EMERYVILLE, Calif.--(BUSINESS WIRE)--Estrella Immunopharma, Inc. (NASDAQ: ESLA) (the “Company”), a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS T-cell therapies to treat cancers and autoimmune diseases, today announced that it has entered into definitive agreements with a single healthcare-focused institutional investor for the purchase and sale of shares of common stock, par value $0.0001 per share (“Common Stock”) and pre-funded warrants (the “Pre-Funded...